N-Acetyl Selank Amidate: A Stabilised Analogue of the Tuftsin-Derived Russian Anxiolytic Peptide

Research summary. N-Acetyl Selank Amidate is a chemically protected analogue of Selank, a heptapeptide developed at the Russian Academy of Medical Sciences as a synthetic analogue of the immunomodulatory peptide tuftsin. The N-acetyl C-amidate modifications cap both peptide termini, blocking aminopeptidase and carboxypeptidase clearance and producing an analogue with extended in vivo stability and improved blood-brain-barrier penetration relative to the unmodified parent. The biological literature on Selank itself is concentrated in a Russian research programme, with limited independent Western replication; the N-acetyl amidated derivative is correspondingly a chemically capped variant of an already-niche compound.

Molecular profile

• Sequence: Ac-Thr-Pro-Arg-Lys-Pro-Glu-Pro-NH₂ (Ac-TPRKEPV-NH₂)
• Molecular formula: C₃₃H₅₇N₁₁O₉
• Molecular weight: ~751.9 g/mol
• PubChem CID: 11765600
• CAS Number: 129954-34-3
• Synonyms: Selanc, TP-7, N-Acetyl Selank, Selank N-acetyl amide
• Class: Stabilised glyproline analogue; tuftsin-derived heptapeptide
• Distinction from parent: Selank itself has the sequence TKPRPGP — the parent compound; N-Acetyl Selank Amidate is the N-acetyl, C-amidated analogue with a slightly different residue arrangement reported in some Russian literature.

Mechanism of action

Selank and its N-acetyl amidated analogue are interpreted as acting through a combination of GABAergic, neurotrophic, and gene-expression-modulating mechanisms:

• Indirect GABAergic modulation. Research has reported that Selank does not bind the GABA-A receptor directly but modulates receptor affinity for GABA, producing anxiolytic effects in rodent models with a profile compared in some published work to benzodiazepines but without the dependence-liability profile reported for GABA-A direct positive allosteric modulators.
• BDNF and neurotrophic signalling. Increases in brain-derived neurotrophic factor (BDNF) expression have been reported in rodent CNS models following Selank administration, alongside changes in serotonin and dopamine handling.
• Gene-expression modulation. Russian-programme research has reported broad gene-expression changes in CNS tissue following Selank administration, with effects spanning genes related to GABAergic signalling, immune modulation, and neuroplasticity.
• Tuftsin-derived immunomodulation. As a tuftsin analogue, Selank inherits a degree of immunomodulatory activity, with reported effects on cytokine balance and immune-cell function.

Why the N-acetyl C-amide modifications matter

Short peptides are typically cleared rapidly in plasma by aminopeptidase and carboxypeptidase activity. The two standard chemical strategies for capping peptide termini are:

• N-terminal acetylation, which blocks aminopeptidase access.
• C-terminal amidation, which blocks carboxypeptidase access and converts the free carboxylic acid to a C-terminal amide.

Together these modifications produce an analogue with extended plasma stability and, in published reports, improved blood-brain-barrier penetration relative to the unmodified parent. This is the same chemical strategy applied to the N-acetyl variants of semax and epithalon described in separate posts.

Preclinical research highlights

Anxiolytic activity in rodent models. Russian-programme research has reported anxiolytic activity in standard rodent paradigms (elevated plus maze, open field, social-interaction tests), with effect sizes interpreted in some published work as comparable to benzodiazepine reference compounds at the doses tested.

Cognitive and learning endpoints. Rodent studies have reported improvements in spatial learning, memory consolidation, and resistance to stress-induced cognitive impairment.

Cerebrovascular and ischaemia models. Selank and its analogues have been studied in rodent models of cerebral ischaemia, with reported reductions in lesion volume and improvements in functional outcomes.

Immune-modulatory effects. Reports include modulation of cytokine balance, with research framing Selank as both a CNS-active anxiolytic and an immunomodulator with peripheral effects.

Limitations of the evidence base

Important caveats apply:

• The supporting biological literature is concentrated in a Russian research programme, and independent Western replication is limited.
• Most published studies are preclinical; human clinical-trial data is concentrated within the Russian regulatory framework rather than in Western trial registries.
• Pharmacokinetic comparison data between Selank and the N-acetyl amidated derivative in matched experimental conditions is sparse in the public literature.
• Selank holds approved status as an anxiolytic in Russia under that regulatory framework but is not approved by the FDA or EMA.

Current research status

N-Acetyl Selank Amidate is an investigational research peptide outside the Russian regulatory framework. It is not approved by the FDA or EMA. Research interest sits at the intersection of anxiolytic-peptide pharmacology, BDNF biology, and short-peptide gene-expression modulation.

For research-supplier contexts, N-Acetyl Selank Amidate is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• N-Acetyl Selank Amidate is a chemically capped analogue of Selank, a tuftsin-derived heptapeptide developed in Russia as a putative anxiolytic.
• The N-acetyl and C-amide modifications block exopeptidase clearance and are reported to extend stability and improve blood-brain-barrier penetration.
• Reported preclinical effects span anxiolytic activity, cognitive and learning endpoints, BDNF elevation, cerebrovascular protection, and immunomodulation.
• The supporting literature is concentrated in a Russian research programme with limited Western replication.
• Selank is not FDA-approved; the N-acetyl amidated derivative is investigational outside the Russian framework.

References

1. Kost NV, Sokolov OY, Kurasova OB, et al. Dipeptidyl peptidase IV cleaves the anxiolytic peptide selank. Bioorg Khim. 2001;27(3):180–183.
2. Medvedev VE, Tereshchenko OY, Israelyan AY, et al. The new domestic anxiolytic Selank: experience with the use in clinical practice. (Original Russian-language clinical and review literature; for foundational reviews of the broader Russian peptide programme, see also Ashmarin IP and Seredenin SB publications.)

---

This article is provided for educational and research purposes only. N-Acetyl Selank Amidate is a research peptide. It is not an FDA- or EMA-approved drug and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.